BioStock: Alligator to maximise immuno-oncology innovation

With ongoing partnering discussion for the phase III trial with mitazalimab, Alligator Bioscience can put more focus on accelerating the development of ATOR-4066. To reach this goal, and push other pipeline projects further, the company now seeks to raise approximately SEK 150.9 million in a rights issue.

Read the article at biostock.se:

Alligator to maximise immuno-oncology innovation - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/